Delivery Order SPE2DR25D3103-SPE2DR26F9N79
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $5,958.75 to AmerisourceBergen Drug Corp for the supply of Trulicity 0.75 mg/0.5 mL pens on August 15, 2025, with an ultimate completion date of August 18, 2025. This firm fixed-price delivery order was awarded without set-aside designations through open competition. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters as a major...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,614.63 to AmerisourceBergen Drug Corp for the supply of Trulicity 0.75 mg/0.5 mL pens on December 10, 2025, with completion scheduled for December 11, 2025. This firm fixed-price delivery order, which carries no set-aside designation, represents a competitively awarded transaction under AmerisourceBergen's larger pharmaceutical supply agreement with the DLA. The product will be performed at the contractor's facility in...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,956.49 to AmerisourceBergen Drug Corp for the supply of Trulicity 0.75 mg/0.5 mL pens on August 25, 2025, with completion scheduled for August 26, 2025. This competitively awarded, firm fixed-price contract represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $1 billion through December 2026. The pharmaceutical distributor...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,928.22 to AmerisourceBergen Drug Corp for the supply of Trulicity 0.75 mg/0.5 mL pens on November 14, 2025, with an ultimate completion date of November 17, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a routine pharmaceutical procurement...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 29, 2025, for the supply of Trulicity 0.75 mg/0.5 mL pens valued at $8,408.40 with a completion date of September 30, 2025. This non-competitive delivery order represents a firm fixed price transaction executed under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion comprehensive pharmaceutical supply agreement running through...
- The Defense Logistics Agency (DLA) awarded a delivery order contract to AmerisourceBergen Drug Corp for the supply of Trulicity 0.75 mg/0.5 mL pens valued at $11,440.24. The contract, which was competitively awarded without set-aside designation, is firm fixed price and has an ultimate completion date of November 25, 2025. AmerisourceBergen will perform the work at its corporate office location in Conshohocken, Pennsylvania. This delivery order falls under the company's larger Indefinite...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for $1,453.70 on November 18, 2025, for the supply of Trulicity 4.5 mg/0.5 mL pens with an ultimate completion date of November 19, 2025. This is a firm fixed price delivery order with no set-aside designation, issued under competitive procedures. The product will be delivered to the company's facility in Conshohocken, Pennsylvania, AmerisourceBergen's headquarters location. This delivery order is a...
- The Defense Logistics Agency awarded a delivery order valued at approximately $14.5K to AmerisourceBergen Drug Corp on December 2, 2025, for the supply of Trulicity 0.75 mg/0.5 mL pens. This is a firm fixed-price, competitively awarded contract with no set-aside designation and a completion date of December 3, 2025. The pharmaceutical product will be supplied to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters and operates as...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $5,955.95 to AmerisourceBergen Drug Corp for the supply of Trulicity 0.75 mg/0.5 mL pens on September 23, 2025, with completion expected by September 24, 2025. This firm fixed-price delivery order, which carries no set-aside designation, represents a competitively awarded transaction under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The pharmaceutical product will be...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,066.90 to AmerisourceBergen Drug Corp for the supply of Trulicity 0.75 mg/0.5 mL pens on August 21, 2025, with completion expected by August 22, 2025. This firm fixed-price delivery order, issued without a set-aside designation, represents a competitive award under the DLA's broader pharmaceutical procurement framework. The product will be delivered to AmerisourceBergen's corporate facility in Conshohocken, Pennsylvania....
- SPE2DR25D3103Indefinite Delivery Contract
- SPE2DR25D3103-SPE2DR26F9N79Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $13,402.18 to AmerisourceBergen Drug Corp for the supply of Trulicity 0.75 mg/0.5 mL pens on December 11, 2025, with an ultimate completion date of December 12, 2025. This firm fixed-price delivery order, which carries no set-aside designation, represents a competitive award under DLA's pharmaceutical supply program. The pharmaceutical will be delivered to the Conshohocken, Pennsylvania location, where AmerisourceBergen Drug Corp maintains its corporate headquarters and primary operations center. This delivery order is issued under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime contract vehicle running through December 2026 that provides comprehensive global pharmaceutical support for military healthcare systems. AmerisourceBergen Drug Corp, a major pharmaceutical distributor serving federal medical procurement needs, maintains extensive experience fulfilling competitively awarded contracts with DLA across a broad range of brand-name and generic medications, vaccines, and medical supplies. The company's portfolio demonstrates consistent capability in delivering diabetes medications, specialty pharmaceuticals, and critical medical commodities to support Department of Defense healthcare programs worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $13.4k | 12/10/25 |